Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.23Last Year’s EPS
1.2Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 6.28%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call demonstrated strong financial growth and strategic achievements, highlighted by significant increases in revenue and successful product launches. Despite some financial setbacks related to non-cash impairments and increased operating expenses, Ligand's robust financial position and promising investment pipeline indicate a positive outlook.Company Guidance
During Ligand's fourth quarter and full-year 2024 earnings call, the company reported impressive financial achievements. Royalty revenue surged by 28%, while core adjusted EPS climbed over 40% to $5.74 per share. The fourth quarter alone saw a 55% increase in royalty revenue compared to the same period in 2023, contributing to over $100 million in operating cash flow for the year. Ligand ended 2024 with more than $250 million in cash and investments, no debt, and access to a $125 million revolving credit facility, expandable to $175 million. The company's strategic focus on economically diversified, infrastructure-light operations has resulted in significant growth, with a five-year royalty receipt outlook projecting a compound annual growth rate of 22% or more from 2024 through 2029.Strong Financial Performance in 2024
Ligand reported a 28% increase in royalty revenue and over 40% growth in core adjusted EPS to $5.74 per share. Fourth-quarter royalty revenue surged by 55% compared to Q4 2023.
Successful Commercial Launches
Verona Pharma’s Ohtuvayre and Merck's Capvaxive exceeded expectations post-launch. Filspari sales increased by approximately 40% in Q4 2024.
Strong Financial Position
Ligand holds over $250 million in cash and investments, no debt, and access to a $125 million revolving credit facility, expandable to $175 million.
Promising New Investments
Ligand led a $75 million financing round for Castle Creek's D-Fi, a phase 3 gene modified autologous cell therapy.
Strategic Business Model Transformation
Reduced cash operating expenses by over 50% and decreased headcount to less than a third of 2022 levels, while growing royalty revenue by nearly 50%.
Positive Guidance for 2025
Projected royalty revenue of $135 million to $140 million, with total revenue guidance of $180 million to $200 million and adjusted EPS of $6 to $6.25.
---
LGND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LGND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $115.01 | $115.67 | +0.57% |
| Nov 07, 2024 | $116.90 | $129.90 | +11.12% |
| Aug 06, 2024 | $99.04 | $93.32 | -5.78% |
| May 07, 2024 | $73.22 | $80.36 | +9.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ligand Pharma (LGND) report earnings?
Ligand Pharma (LGND) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Ligand Pharma (LGND) earnings time?
Ligand Pharma (LGND) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGND EPS forecast?
LGND EPS forecast for the fiscal quarter 2025 (Q1) is 1.23.
---